<DOC>
	<DOC>NCT01006499</DOC>
	<brief_summary>The investigators aim is to investigate whether adjuvant Pentoxifylline , IgM enriched IVIG or Pentoxifylline plus IgM-enriched IVIG reduced mortality from Neonatal sepsis.</brief_summary>
	<brief_title>Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>: All infants thought/diagnosed to have late or early onset sepsis. Pentoxifylline or Pentaglobin has already been given Pentoxifylline or Pentaglobin is thought to be needed or contraindicated Major congenital anomaly Intraventricular hemorrhage (Grade 3 veya 4) Congenital infections Inborn errors of metabolism</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>neonatal sepsis</keyword>
	<keyword>pentoxyfilline</keyword>
	<keyword>pentaglobin</keyword>
	<keyword>biomarker</keyword>
	<keyword>To reduce mortality in neonatal sepsis</keyword>
</DOC>